<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934336</url>
  </required_header>
  <id_info>
    <org_study_id>2007-A01036-47</org_study_id>
    <nct_id>NCT00934336</nct_id>
  </id_info>
  <brief_title>Importance in Type 1 Diabetes Patients of an Optimized Control of Post-Prandial Glycaemia on Oxidant Stress Prevention</brief_title>
  <acronym>ITOPOS</acronym>
  <official_title>Importance in Type 1 Diabetes Patients of an Optimized Control of Post-Prandial Glycaemia on Oxidant Stress Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether postprandial hyperglycaemia plays an important&#xD;
      role in oxidative stress phenomena and influences their harmful effects on the arterial wall.&#xD;
&#xD;
      25 type 1 diabetic patients practicing FIT and with an HbA1c value of 8 percent or less at&#xD;
      the beginning of the study will be recruited. The 25 control subjects will be recruited after&#xD;
      the patients, so that they can be paired by age and sex.&#xD;
&#xD;
      Patients will be randomized via an alternative cross over study design for 2 periods of 3&#xD;
      months, i.e. preprandial or postprandial injection of an ultra fast acting analog. During the&#xD;
      6 months of the study, slow acting analog doses will be adjusted on the basis of basal&#xD;
      glycaemia values. The fast acting analog doses will be adjusted on the basis of an optimized&#xD;
      algorithm available on each patient's PDA phone electronic diary.&#xD;
&#xD;
      Blood and urine samples will be collected at M0, M3 and M6 to evaluate the stress oxidant&#xD;
      grade and its consequence on atherogenesis:&#xD;
&#xD;
      Oxidative Stress evaluation: plasma parameters (lipid peroxide derivatives, semicarbazide&#xD;
      sensitive oxidase amine activity), erythrocyte and leukocyte cell parameters (reduced and&#xD;
      oxidised glutathion, dismutase superoxide activity (SOD) Cu and Mn dependent, glutathion&#xD;
      peroxidase, and catalase), urinary parameters (isoprostane F2) Evaluation of consequences of&#xD;
      oxidative stress on atherogenesis processes: inflammatory parameters (CRP, TNFa, IL 6),&#xD;
      adhesion molecules (VCAM 1, ICAM 1, P selectine), adipokines (leptine, resistine,&#xD;
      adiponectine), coagulation factors (PAI 1), platelet and endothelial microparticles, The pre&#xD;
      and postprandial glycaemic stability of each patient will be monitored using PDA phone&#xD;
      systems, and HbA1c will be measured at M0, M3 and M6.&#xD;
&#xD;
      Expected results and outcomes:&#xD;
&#xD;
      It is important to know if, in patients with comparable glycaemic stability, these two&#xD;
      insulin treatment regimens are associated with significant differences in oxidative stress&#xD;
      and anti oxidant defenses.&#xD;
&#xD;
      These results may help us to define a postprandial insulin treatment regimen (which is more&#xD;
      flexible as regards meals) or a preprandial insulin treatment regimen (less flexible for&#xD;
      meals but maybe less harmful in terms of limitation of oxidative stress).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assay of isoprostane-F2, an indicator of lipid peroxidase derivative production, in the 24 hour urine</measure>
    <time_frame>T0, T3 months, T6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>preprandial injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pre-prandial injection of an ultra-fast-acting analog during 3 months, then post-prandial injection of an ultra-fast-acting analog during 3 other months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>post-prandial injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>post-prandial injection of an ultra-fast-acting analog during 3 months then pre-prandial injection of an ultra-fast-acting analog during 3 other months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic and preventive strategies</intervention_name>
    <description>These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).</description>
    <arm_group_label>preprandial injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic and preventive strategies</intervention_name>
    <description>These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).</description>
    <arm_group_label>post-prandial injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 Diabetes&#xD;
&#xD;
          -  treaties by basal / bolus with a ultra rapid analogue or a pump with a ultra rapid&#xD;
             analogue&#xD;
&#xD;
          -  Adults between 18 and 50 years old&#xD;
&#xD;
          -  Patients practicing FIT&#xD;
&#xD;
          -  Written informed consent obtained prior to enrollment in the study&#xD;
&#xD;
          -  HbA1c ≤ 8%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes other than DT1&#xD;
&#xD;
          -  Complications: coronary or peripheral arteriopathy&#xD;
&#xD;
          -  Pathologies being able to interfere with the study: HTA, dyslipidemia, nicotinism,&#xD;
             inflammatory , cancerous pathology…&#xD;
&#xD;
          -  Psychiatric pathologies incompatible with the study&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FEVE Bruno, MD PH</last_name>
    <role>Study Chair</role>
    <affiliation>Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CHARPENTIER Guillaume, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Sud Francilien</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH sud francilien</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>August 5, 2015</last_update_submitted>
  <last_update_submitted_qc>August 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

